Your AI-Trained Oncology Knowledge Connection!

Patient Profiles in HER2-Positive Breast Cancer : Episode 11

Video

May 19, 2022

Patient Profile 1: 62-Year-Old Woman With Metastatic Breast Cancer

Author(s):

Breast medical oncologist, Tiffany Traina, MD, shares a clinical scenario of a patient with HER2+ metastatic breast cancer and discusses her treatment approach in the neoadjuvant, adjuvant, and metastatic settings.

EP: 1.HER2+ Breast Cancer: Overview of the Treatment Armamentarium

EP: 2.Selecting and Sequencing Therapy for HER2+ Breast Cancer

EP: 3.Recent Trial Data in HER2+ Metastatic Breast Cancer

EP: 4.Patient Profile 1: Frontline Therapy for HER2+ mBC

EP: 5.Patient Profile 1: Second-Line Therapy for HER2+ mBC

EP: 6.Patient Profile 1: Sequencing Therapies in HER2+ mBC

EP: 7.Patient Profile 2: Patient with Triple-Positive mBC

EP: 8.Patient Profile 2: Second-Line Therapy for Triple-Positive mBC

EP: 9.Patient Profile 2: 3L Therapy for Triple-Positive mBC

EP: 10.Considering Novel Therapy for HER2+ Metastatic Breast Cancer

Now Viewing

EP: 11.Patient Profile 1: 62-Year-Old Woman With Metastatic Breast Cancer

EP: 12.Patient Profile 1: Trastuzumab Deruxtecan for HER2+ Metastatic BC

EP: 13.Patient Profile 2: 26-Year-Old Woman With Triple Positive Breast Cancer

EP: 14.Patient Profile 2: Strategies for Managing Brain Metastases in HER2+ Metastatic Breast Cancer

EP: 15.Patient Profile 2: How Should T-DM1 Be Sequenced in HER2+ mBC?

EP: 16.Patient Profile 2: Clinical Utility of the HER2CLIMB Regimen for HER2+ mBC

EP: 17.Patient Profile 2: Treatment Sequencing in a Patient with Progressive Brain Metastases

EP: 18.Patient Profile 3: 43-Year-Old Woman With Metastatic Breast Cancer Progressing Through Multiple Lines of Therapy

EP: 19.Patient Profile 3: Treatment Sequencing in a Patient with metastatic HER2+ Breast Cancer

EP: 20.Patient Profile 4: Strategies for Managing ILD in Patients Receiving Trastuzumab Deruxtecan

EP: 21.Patient Profile 4: Managing AEs in Patients Receiving Treatment for HER2+ BC

EP: 22.Patient Profile 5: Strategies for Managing Elevated Liver Function Tests in Patients on the HER2CLIMB Regimen

EP: 23.Future Directions in the Management of HER2+ Breast Cancer

Stay up to date on the most recent and practice-changing oncology data

Subscribe Now!

Latest CME

View All

Video

Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation

Jun 6th 2025 - Jul 12th 2025

online-activity

Video

Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC

Jun 6th 2025 - Jul 12th 2025

online-activity

Video

Evolving Treatment Strategies in Pancreatic Cancer: Current Standards, Emerging Targets, and the Role of Molecular Testing

Jun 5th 2025 - Jul 12th 2025

online-activity

Latest Conference Coverage

Pirtobrutinib Improves Patient-Reported Outcomes in Relapsed/Refractory CLL/SLL

MAIC Analysis Shows PFS Favorability With Zanubrutinib vs Acalabrutinib/Venetoclax in CLL

Isa-KRd Yields Prolonged MRD Negativity vs KRd in Newly Diagnosed Myeloma

Elranatamab Triplet Yields Nearly 100% ORR in Newly Diagnosed Multiple Myeloma

View More Latest Conference Coverage

Advertise

About OncLive

Editorial Board

MJH Life Sciences brands

Privacy

Terms & Conditions

Do Not Sell My Information

Contact Info

2 Commerce Drive
Cranbury, NJ 08512

Patient Profile 1: 62-Year-Old Woman With Metastatic Breast Cancer

EP: 1.HER2+ Breast Cancer: Overview of the Treatment Armamentarium

EP: 2.Selecting and Sequencing Therapy for HER2+ Breast Cancer

EP: 3.Recent Trial Data in HER2+ Metastatic Breast Cancer

EP: 4.Patient Profile 1: Frontline Therapy for HER2+ mBC

EP: 5.Patient Profile 1: Second-Line Therapy for HER2+ mBC

EP: 6.Patient Profile 1: Sequencing Therapies in HER2+ mBC

EP: 7.Patient Profile 2: Patient with Triple-Positive mBC

EP: 8.Patient Profile 2: Second-Line Therapy for Triple-Positive mBC

EP: 9.Patient Profile 2: 3L Therapy for Triple-Positive mBC

EP: 10.Considering Novel Therapy for HER2+ Metastatic Breast Cancer

EP: 11.Patient Profile 1: 62-Year-Old Woman With Metastatic Breast Cancer

EP: 12.Patient Profile 1: Trastuzumab Deruxtecan for HER2+ Metastatic BC

EP: 13.Patient Profile 2: 26-Year-Old Woman With Triple Positive Breast Cancer

EP: 14.Patient Profile 2: Strategies for Managing Brain Metastases in HER2+ Metastatic Breast Cancer

EP: 15.Patient Profile 2: How Should T-DM1 Be Sequenced in HER2+ mBC?

EP: 16.Patient Profile 2: Clinical Utility of the HER2CLIMB Regimen for HER2+ mBC

EP: 17.Patient Profile 2: Treatment Sequencing in a Patient with Progressive Brain Metastases

EP: 18.Patient Profile 3: 43-Year-Old Woman With Metastatic Breast Cancer Progressing Through Multiple Lines of Therapy

EP: 19.Patient Profile 3: Treatment Sequencing in a Patient with metastatic HER2+ Breast Cancer

EP: 20.Patient Profile 4: Strategies for Managing ILD in Patients Receiving Trastuzumab Deruxtecan

EP: 21.Patient Profile 4: Managing AEs in Patients Receiving Treatment for HER2+ BC

EP: 22.Patient Profile 5: Strategies for Managing Elevated Liver Function Tests in Patients on the HER2CLIMB Regimen

EP: 23.Future Directions in the Management of HER2+ Breast Cancer

Newsletter

Latest CME

Evolving Treatment Strategies in Pancreatic Cancer: Current Standards, Emerging Targets, and the Role of Molecular Testing

Medical Crossfire®: The Precision Path for HER2 and TROP2-Targeted Treatments in Non–Small Cell Lung Cancer

Medical Crossfire®: Harnessing the Power of Modern Therapies in Newly Diagnosed Multiple Myeloma

Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation

Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC

Evolving Treatment Strategies in Pancreatic Cancer: Current Standards, Emerging Targets, and the Role of Molecular Testing

Medical Crossfire®: The Precision Path for HER2 and TROP2-Targeted Treatments in Non–Small Cell Lung Cancer

Medical Crossfire®: Harnessing the Power of Modern Therapies in Newly Diagnosed Multiple Myeloma

Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation

Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC

Evolving Treatment Strategies in Pancreatic Cancer: Current Standards, Emerging Targets, and the Role of Molecular Testing

Medical Crossfire®: The Precision Path for HER2 and TROP2-Targeted Treatments in Non–Small Cell Lung Cancer

Medical Crossfire®: Harnessing the Power of Modern Therapies in Newly Diagnosed Multiple Myeloma

Latest Conference Coverage